Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Interest Expenses (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Interest Expenses for 4 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses rose 13.27% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Dec 2025, up 13.57% year-over-year, with the annual reading at $11.5 million for FY2025, 13.57% up from the prior year.
  • Interest Expenses for Q4 2025 was $2.8 million at Centessa Pharmaceuticals, down from $2.9 million in the prior quarter.
  • The five-year high for Interest Expenses was $2.9 million in Q3 2025, with the low at $1.5 million in Q1 2022.
  • Average Interest Expenses over 4 years is $2.4 million, with a median of $2.5 million recorded in 2024.
  • The sharpest move saw Interest Expenses soared 56.33% in 2023, then fell 3.54% in 2024.
  • Over 4 years, Interest Expenses stood at $2.2 million in 2022, then increased by 16.66% to $2.6 million in 2023, then dropped by 3.54% to $2.5 million in 2024, then rose by 13.27% to $2.8 million in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $2.8 million, $2.9 million, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.